Symbol="SYRS"
AssetType="Common Stock"
Name="Syros Pharmaceuticals Inc"
Description="Syros Pharmaceuticals, Inc., a biopharmaceutical company, is focused on developing treatments for cancer and monogenic diseases and building a line of gene control drugs. The company is headquartered in Cambridge, Massachusetts."
CIK="1556263"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="81488000"
EBITDA="-139812000"
PERatio="None"
PEGRatio="0"
BookValue="3.537"
DividendPerShare="0"
DividendYield="0"
EPS="-0.24"
RevenuePerShareTTM="0.381"
ProfitMargin="0"
OperatingMarginTTM="-15.99"
ReturnOnAssetsTTM="-0.581"
ReturnOnEquityTTM="-1.824"
RevenueTTM="8924000"
GrossProfitTTM="14880000"
DilutedEPSTTM="-0.24"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.549"
AnalystTargetPrice="25.25"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="2.99"
PriceToBookRatio="0.579"
EVToRevenue="2.578"
EVToEBITDA="0.99"
Beta="1.612"
num_52WeekHigh="9.25"
num_52WeekLow="2.42"
num_50DayMovingAverage="3.509"
num_200DayMovingAverage="3.589"
SharesOutstanding="20710000"
DividendDate="None"
ExDividendDate="None"
symbol="SYRS"
open="3.98"
high="3.98"
low="3.89"
price="3.89"
volume="14485.00"
latest_trading_day="2023-08-29"
previous_close="4.00"
change="-0.11"
change_percent="-2.7500%"
aroon_positive_momentum_days="54"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="54"
Volume_recent_avg="74470"
Change_recent_avg="0.01"
Delta_recent_avg="0.19"
Variance_recent_avg="0.09"
Change_ratio_recent_avg="0.26"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="54"
Aroon_momentum_negative="46"
image_negative_thumbnail_id_1="175"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0001.jpeg"
image_negative_thumbnail_id_2="1140"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0173.jpeg"
image_neutral_thumbnail_id_1="530"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0069.jpeg"
image_neutral_thumbnail_id_2="541"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0058.jpeg"
image_positive_thumbnail_id_1="970"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0132.jpeg"
image_positive_thumbnail_id_2="958"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0120.jpeg"
image_professor_thumbnail_id_1="1193"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0027.jpeg"
image_professor_thumbnail_id_2="1190"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0024.jpeg"
